AstraZeneca and Chi-Med Report Positive Data from Cancer Drug Combo

AstraZeneca and Hutchison China MediTech announced positive preliminary data from a Phase Ib trial of savolitinib (AZD6094), a c-Met inhibitor AstraZeneca in-licensed from Chi-Med in 2011. Savolitinib was tested in combination with AZD9291, another AstraZeneca investigational molecule, which targets EGFR. Of the 11 evaluable patients in the study, six partial responses (confirmed and unconfirmed) have been observed to date. More details.... Stock Symbols: (NYSE: AZN) (AIM: HCM) Share this with colleagues: // //